Teva Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Teva Pharma (TEVA) Tops Q3 EPS by 11c; Raises Outlook
November 1, 2018 7:01 AM EDTTeva Pharma (NYSE: TEVA) reported Q3 EPS of $0.65, $0.11 better than the analyst estimate of $0.54. Revenue for the quarter came in at $4.5 billion versus the consensus estimate of $4.53 billion.
GUIDANCE:
Teva Pharma sees FY2018 EPS of $2.80-$2.95, versus prior of $2.55-$2.80... More
